Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries

Circulation

Volumn 97, Issue 1, 1998, Pages 82-90

  Mark Jenkins, G ^a   Crow, Michael T ^a,c   Bilato, Claudio ^a   Gluzband, Yehezkiel ^a   Ryu, Wang Seong ^a   Li, Zhihe ^a   Stetler Stevenson, William ^a,b   Nater, Cynthia ^a   Froehlich, Jeffrey P ^a   Lakatta, Edward G ^a   Cheng, Linda ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Carotid arteries; Extracellular matrix; Metalloproteinases; Neointima; Restenosis

Indexed keywords

GELATINASE A; MATRIX METALLOPROTEINASE;

ANIMAL TISSUE; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; BALLOON CATHETER; CAROTID ARTERY; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME LOCALIZATION; EXTRACELLULAR MATRIX; NONHUMAN; PRIORITY JOURNAL; RAT; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TURNOVER TIME;

EID: 0345516003     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.97.1.82     Document Type: Article

References (56)

1. Gruentzig AR, King SB III, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. N Engl J Med. 1987;316:1127-1132.
2. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty. N Engl J Med. 1988;318:1734-1737.
3. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N, Horiuchi H, Ohisho H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988;12:616-623.
4. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, deFeyter PJ, van den Brand M, Reiber JH, ten Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, and 3 months. Circulation. 1988;77:361-371.
5. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318:1714-1719.
6. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation, 1991;84:1426-1436. Editorial.
7. Churchill DA, Siegel CO, Dougherty KG, Raizner AE, Minor ST. Failure of enalapril to reduce coronary restenosis in a swine model Circulation. 1991;84(suppl II):II-1183. Abstract.
8. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia: a review. J Vasc Surg. 1991;13:885-891.
9. O'Keefe JH, McCallister BD, Bateman TM, Kuhnlem DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992:19:1597-1600.
10. Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty: potential biologic determinants and role of intimai hyperplasia. Circulation. 1989;79:1374-1387.
11. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatt AJ, Mowery J. Atherosclerosis: potential targets for stabilization and regression. Circulation. 1992;86(suppl III):III-117-III-123.
12. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20: 1284-1293.
13. Campbell JH, Black MJ, Campbell GR. Replication of smooth muscle cells in atherosclerosis and hypertension. Atherosclerosis Rev. 1989;19:1-53.
14. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med. 1986;314:488-500.
15. Casscells W. Smooth muscle cell growth factors. Prog Growth Factor Res. 1991;31:177-206.
16. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci U{ths}S{ths}A.. 1989;86: 8412-8416.
17. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992; 86(suppl III):III-47-III-52.
18. Ip JH, Fuster V, Israel D, Badiman L, Badiman J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17(suppl B):77B-88B.
19. Clowes AW, Reidy M, Clowes MM. Kinetics of cellular proliferation after arterial injury: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
20. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U{ths}S{ths}A.. 1991;88:3739-3743.
21. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
22. Brenner CA, Adler RR, Rappolee DA, Pederson RA, Werb Z. Genes for extracellular-matrix-degrading metalloproteinases and their inhibitor, TIMP, are expressed during early mammalian development. Genes Dev. 1989;3:848-859.
23. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Biol. 1995;7:728-735.
24. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990;9:289-303.
25. Mignatti P, Robbins E, Rifken DB. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. I986;47: 487-498.
26. Mignatti P, Rifkin D. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993;73:161-195.
27. Liotta, LA, Rao AN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest. 1983;49:636-649.
28. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
29. Liotta LA, Steeg PS, Stettler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64: 327-336.
30. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.
31. Galis ZS, Sukhove GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix-degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
32. Bendeck MP, Zemp N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
33. Zempo N, Kenagy RD, Au YPT, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg. 1994;20:209-217.
34. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res. 1996;78:38-43.
35. Pauly RR. Passaniti A, Bilato C, Monticone R, Cheng L, Papdaopoulos N, Gluzband YA, Smith L, Weinstein C. Lakatta E, Crow MT. The migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
36. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDA type IV Collagenase. J Biol Chem. 1995;270:5331-5338.
37. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Marguiles IMK, Liotta LA. The activation of human type IV collagenase proenzyme. J Biol Chem. 1989;264:1353-1356.
38. Brown PD. Kleiner DE, Unsworth EJ, Steder-Stevenson WG. Cellular activation of the 72 kDa type IV collagenase/TIMP-2 complex. Kidney Int. 1993;43:163-170.
39. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Motoharu S. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature. 1994;370:61-65.
40. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-5299.
41. Zheng JS, Boluyt MO, O'Neill LO, Crow MT, Lakatta EG. Extracellular ATP induces immediate-early gene expression but not cellular hypertrophy m neonatal cardiac myocytes. Circ Res. 1994;74:1034-1041.
42. Okada A, Belloco JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P. Membrane-type matrix metalloproteinase (MT-MMP) is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A.. 1995;92:2730-2734.
43. Fernandez PL, Merino MJ, Nogales FF, Charonis AS, Steder-Stevenson W, Liotta L. Immunohistochemical profile of basement membrane proteins and 72 kilodalton type IV collagenase in the implantation placental site. Lab Invest. 1992;66:572-579.
44. Strauss BH, Robinson R, Batchelor WB, Chisholm RJ, Ravi G, Natarajan MK, Logan RA, Mehta SR, Ley DE, Ezrin AM, Keeley FW. In vivo collagen turnover following experimental balloon angioplasty injury and the role of metalloproteinases. Circ Res. 1996;79:541-550.
45. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH, Fabunmi RP, Groves PH, Davies M, Newby AC. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res. 1996;79:1177-1187.
46. Schwartz SM. deBlois D, O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res, 1995;77:445-465.
47. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He C. Human 72-kDa type IV collagenase forms a complex with a tissue inhibitor of metalloproteinase. Proc Natl Acad Sci U S A.. 1989;86:8207-8211.
48. Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor or metalloproteinases-2. J Biol Chem. 1991;266:13070-13075.
49. Ward RV, Atkinson SJ, Slocombe PM, Docherty AJP, Reynolds JJ, Murphy G. Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta. 1991;1079:242-246.
50. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem. 1990;265:13933-13938.
51. Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem. 1995;270:23013-23020.
52. Eckes B, Mauch C, Huppe G, Krieg T. Downregulation of collagen synthesis in fibroblasts within three dimensional collagen lattices involves transcriptional and post-transcriptional mechanisms. FEBS Lett. 1993;318: 129-133.
53. Skinner MP, Raines EW, Ross R. Dynamic expression of a1b1 and a2b1 integrin receptors by human vascular smooth muscle cells. Am J Pathol. 1994;145:1070-1081.
54. 3 Integrin expression in normal and atherosclerotic artery. Circ Res. 1995; 77:1129-1135.
55. 3 integrin complex is reversed by activated calcium/calmodulin-dependent protein kinase II. J Clin Invest. 1997;100: 693-704.
56. 3. Cell. 1996;85:683-693.